Callan JMB Inc. Announces Pricing of $5.12 Million Initial Public Offering on Nasdaq

Callan JMB Inc. announces IPO of 1,280,000 shares at $4.00 each, raising approximately $5.12 million, trading begins February 5, 2025.

Quiver AI Summary

Callan JMB Inc. has announced the pricing of its initial public offering (IPO) of 1,280,000 shares of common stock at $4.00 per share, aiming to raise about $5.12 million before expenses. The shares will begin trading on the Nasdaq under the ticker symbol "CJMB" on February 5, 2025, with the offering expected to close around February 6, 2025. The company plans to use the proceeds for sales support, marketing, and general corporate purposes. Alexander Capital L.P. is the lead underwriter, with legal counsel services provided by Sichenzia Ross Ference Carmel LLP and Sullivan & Worcester LLP. This announcement includes forward-looking statements and advises potential investors to review the prospectus and risk factors associated with the offering, which is registered with the U.S. Securities and Exchange Commission.

Potential Positives

• Callan JMB Inc. has successfully priced its initial public offering (IPO) at $4.00 per share, raising approximately $5,120,000 in gross proceeds before expenses, indicating strong market interest and financial support for the company's growth.
• The offering allows Callan to expand its operations by allocating the net proceeds toward sales support, marketing, customer expansion, and working capital, which is critical for enhancing its service capabilities in the healthcare logistics sector.
• The company is set to begin trading on the Nasdaq Capital Market under the ticker symbol "CJMB," which could enhance its visibility and shareholder base in the public market.
• Granting underwriters a 45-day option to purchase additional shares may lead to further capital influx, supporting the company's strategic financial goals.

Potential Negatives

• The initial public offering price of $4.00 per share may indicate a lack of strong investor confidence, potentially reflecting lower valuation expectations for the company.
• The total gross proceeds of approximately $5.12 million may be considered modest for a company seeking to empower the healthcare industry and expand its operations substantially.
• The presence of conditions for closing the offering could introduce uncertainties that may affect the company's financial planning and operations shortly after going public.

FAQ

What is the initial public offering price of Callan JMB Inc.'s shares?

The initial public offering price is set at $4.00 per share.

How many shares were offered in Callan JMB's IPO?

Callan JMB offered 1,280,000 shares in its IPO.

When will Callan JMB shares start trading on Nasdaq?

Shares are expected to begin trading on February 5, 2025, under the ticker symbol “CJMB.”

What will the proceeds from the IPO be used for?

The proceeds will be used for sales support, marketing, customer expansion, and general corporate purposes.

Who are the underwriters for Callan JMB's offering?

The managing underwriter is Alexander Capital L.P., with Paulson Investment Company, LLC as joint book-runners.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

Full Release

SPRING BRANCH, Texas, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan” or the “Company”)

, an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services, today announced the pricing of its initial public offering (the “

Offering

”) of 1,280,000 shares (the “

Shares

”) of common stock (“

Common Stock

”) at an initial public offering price of $4.00 per Share for a total of approximately $5,120,000 of gross proceeds to the Company before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, Callan has granted the underwriters a 45-day option to purchase, at the public offering price, up to an additional 192,000 shares of Common Stock at the public offering price, less the underwriting discounts and commissions.

The Shares are expected to begin trading on the Nasdaq Capital Market on February 5, 2025, under the ticker symbol “CJMB”. The Offering is expected to close on or about February 6, 2025, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds of the Offering primarily for sales support, marketing, customer expansion and general corporate purposes, including working capital.

Alexander Capital L.P. (“

Alexander

”) is the managing underwriter for the Offering, and Alexander and Paulson Investment Company, LLC are acting as joint book-runners for the Offering. Sichenzia Ross Ference Carmel LLP is serving as counsel to the Company, and Sullivan & Worcester LLP is serving as counsel to Alexander in connection with the Offering.

A registration statement on Form S-1, as amended (File No. 333-282879), relating to the Shares described above was filed with the U.S. Securities and Exchange Commission (“

SEC

”) and was declared effective on February 4, 2025. The Offering is being made only by means of a prospectus. A copy of the final prospectus relating to the Offering may be obtained, when available, from Alexander Capital, L.P., via email:



info@alexandercapitallp.com




,

or by calling +1 (212) 687-5650, or by standard mail at Alexander Capital L.P., 10 Drs James Parker Blvd, Suite 202 Red Bank, New Jersey 07701, Attention: Equity Capital Markets. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at



www.sec.gov




.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Callan JMB



Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through exceptional fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.

Forward Looking Statements:



This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “

Exchange Act

”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at


http://www.sec.gov/



.

Investor Contacts:



Valter Pinto, Managing Director


KCSA Strategic Communications




CallanJMB@kcsa.com




212.896.1254

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.